Salute e Benessere

Collagen Peptides Market Size to Grow USD 859 Million by 2029 at a CAGR of 26.7%…

Major Factors Driving the Growth of the the Collagen Peptides Market: Major Factors Driving the Growth of the the Collagen Peptides Marke t: One of the main factors propelling the market for collagen peptides revenue growth is consumer awareness of their skin and health. The Collagen Peptides market is expanding as a result of rising interest in cosmetics and nutricosmetics as well as rising demand for meals and drinks that are functional and fortified. Collagen peptides are...
PR Newswire
07/08/2023

Contrast Enhanced Ultrasound Market worth $2.1 billion | MarketsandMarkets

The major factors driving the growth of this market include the rising prevalence of chronic diseases and technological developments. Furthermore, contrast-enhanced ultrasound procedures help clinicians with the early detection of chronic diseases and ultimately improve patient outcomes. Contrast agents offer exceptional imaging image clarity and also enable the visualization of blood flow. The major factors driving the growth of this market include the rising prevalence of chronic diseases…
PR Newswire
07/08/2023

Revolutionary Technique Offers Hope for Hair Restoration in Individuals of…

Led by Dr. Sanusi Umar from the Division of Dermatology, Harbor-UCLA Medical Center, Torrance, and Dr. U Hair and Skin Clinic in Manhattan Beach, the study's multinational team of experts from seven countries introduces the skin-responsive follicular unit excision (FUE) device UGraft Zeus® (Manhattan Beach, CA). This cutting-edge device uniquely adapts to hair curliness, skin thickness, and firmness in hair transplant patients, setting a new standard in hair restoration procedures. Led by Dr...
PR Newswire
07/08/2023

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Jarmo Halonen

BBS-Bioactive Bone Substitutes Plc, Company announcement, management transactions, 7 August 2023 at 16.00 (EEST)BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Jarmo HalonenThis Company announcement contains information on the following management transactions: Subscription of shares with warrants (TO1) 24 and 25 November 2022Discposal of shares on 22 December 2022Subscription of shares in share issues on 21 and 29 June 2023 ...
Nasdaq GlobeNewswire
07/08/2023

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Ahti Paananen

BBS-Bioactive Bone Substitutes Plc, Company announcement, management transactions, 7 August 2023 at 16.00 (EEST)BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Ahti PaananenThis Company announcement contains information on the following management transactions: Subscription of shares with warrants (TO1) 5 December 2022 ____________________________________________Person subject to the notification requirementName: Paananen AhtiPosition: Member of the...
Nasdaq GlobeNewswire
07/08/2023

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc, Company announcement, management transactions, 7 August 2023 at 16.00 (EEST)BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara This Company announcement contains information on the following management transactions: Subscription of shares with warrants (TO1) 5 December 2022Subscription of shares with warrants (TO2) 29 May 2023Subscription of shares in share issue on 26 June 2023Received shares without...
Nasdaq GlobeNewswire
07/08/2023

Ligandal Inc. Appoints Tushar Nuwal as Chief Operating Officer and Chief…

Mr. Nuwal is a global pharmaceutical veteran. His leadership spans across R&D, manufacturing, product & launch management, operations, business & corporate development, licensing, portfolio, and commercial strategy. His most recent role was Vice President at Polypid Inc., where he led BD&L. Prior to that, he was Executive Director of BD&L at Sandoz, a $10 billion division of Novartis. Mr. Nuwal is a global pharmaceutical veteran. His leadership spans across R&D…
PR Newswire
07/08/2023

Bio-Gate AG signs LOI with North American medical device manufacturer for trauma…

Industrial News Service
07/08/2023

Blood Culture Tests Market worth $7.6 billion | MarketsandMarkets

Growth in this market is primarily fueled by growing demand for rapid diagnostic techniques, high prevalence of infectious diseases, growing incidence of sepsis cases and high-cost treatment, rising geriatric population and high incidence of bloodstream infections. Alternatively, lack of trained laboratory technicians and high cost of automated instruments are expected to restrain the market growth in the upcoming years. Growth in this market is primarily fueled by growing demand for rapid...
PR Newswire
07/08/2023

Navamedic ASA: Invitation to 2023 2nd quarter presentation

Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail:kathrine@navamedic.com Lars Hjarrand,CFO, +47 917 62 842 E-mail:lars.hjarrand@navamedic.com About Navamedic: Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading...
PR Newswire
07/08/2023

BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update

Significant pipeline advancement highlighted by the initiation of BNT316/ONC-392 Phase 3 pivotal trial and multiple trials planned to start across the oncology portfolioPositive data updates across multiple technology platforms including ADC candidate BNT323/DB-1303, anti-CTLA4 monoclonal antibody candidate BNT316/ONC-392 and CAR-T candidate BNT211 Preparation for launch of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine as recommended by the U.S. Food and Drug Administration...
Nasdaq GlobeNewswire
07/08/2023

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of…

The data have been generated in collaboration with XNK's external partners, Anders Ullén and Fernanda Costa Svedman at the Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, for the bladder cancer abstract, and Abhishek Maiti and Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract. The data have been generated in collaboration with XNK's external partners, Anders Ullén andFernanda Costa Svedmanat the...
PR Newswire
07/08/2023

EQT Private Equity to sell Schülke, a sustainability leader in infection…

EQT Private Equity acquired Schülke in July 2020 with a vision to focus the business portfolio, accelerate growth in core markets, invest in sustainability and innovation, and expand its geographical footprint. Together with the Schülke management team, EQT Private Equity has delivered on this vision. Schülke repositioned to focus entirely on the healthcare and life science market, which included the sale of the Personal Care business and the discontinuation of other non-healthcare related…
PR Newswire
07/08/2023

Delhi based Manipal Hospital Extends its Healthcare Services with Mega Health…

"We are delighted to be organizing this Mega Healthcare Camp in Uzbekistan," said Dr. Shailendra Lalwani, Head of the Department of Liver Transplant and HPB Surgery. "This is a great opportunity for us to share our expertise with the people of Uzbekistan and help them improve their health and well-being. We are confident that this camp will make a positive impact on the lives of many people." "We are delighted to be organizing this Mega Healthcare Camp…
PR Newswire
07/08/2023

SANY Engineering Vehicles Unveils New Range of Intelligent New Energy Dump…

Yu Hongfu, President of SANY Heavy Industry, emphasized their commitment to the national 'Dual Carbon Strategy' at the product launch, and stated the new products marked the first release since SANY Engineering Vehicles' creation, covering hybrid, heavy-duty, and composite platforms. Yu Hongfu, President of SANY Heavy Industry, emphasized their commitment to the national 'Dual Carbon Strategy' at the product launch, and stated the new products marked the first release since SANY Engineering...
PR Newswire
07/08/2023

VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter…

As the company's international flagship product, VenusP-Valve received CE marking under the Medical Devices Regulation (MDR) on April 8th, 2022, becoming the first Class III implantable cardiovascular device approved under the new MDR. To date, VenusP-Valve has been approved in more than thirty countries including China, the United Kingdom, Italy, Spain, Denmark, Greece, France, Germany, Poland, Switzerland, etc., and its implantations enjoy continuous growth in new hospitals and centers. As...
PR Newswire
07/08/2023

Avance Clinical Earns Frost & Sullivan's 2023 Best Practices Customer Value…

Avance Clinical's services span the entire clinical trial process, from early-stage development to late-stage studies, supporting the ever-evolving demands of biotechnology research and development. It offers up-to-date strategic guidance on study design, regulatory compliance, and protocol development, ensuring trials comply with the rigorous requirements of regulatory authorities globally. Avance Clinical's services span the entire clinical trial process, from early-stage development to...
PR Newswire
07/08/2023

Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus…

Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22 days post a single vaccination.A fast and durable response was confirmed with high levels of immunity at both 2 weeks and 6 months post a single vaccination.Regulatory submissions planned for 2024Conference call Monday, August 7 at 2 pm CEST / 8 am EDTCOPENHAGEN, Denmark, August 6, 2023– Bavarian Nordic A/S (OMX: BAVA) announced...
Nasdaq GlobeNewswire
06/08/2023

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved…

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45 Mental health conditions are the leading cause of maternal mortality 1with PPD among the most common complications during and after pregnancy 2 CAMBRIDGE, Mass., Aug.04, 2023(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) and Sage Therapeutics, Inc...
Nasdaq GlobeNewswire
05/08/2023

Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New…

Vivoryon Therapeutics N.V.Extraordinary General Meetingto Confirm New Executive Director Appointments to the Board , Being Held on September 15, 2023Halle (Saale) / Munich, Germany, August 4 , 2023– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon , or the Company ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins,...
Nasdaq GlobeNewswire
04/08/2023

Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as…

Vivoryon Therapeutics N.V.Announces Proposed Appointment of Dr. Frank Weber as Chief Executive OfficerFrank Weber, MD, current Chief Medical Officer (CMO) ,promoted to Chief Executive Officer (CEO) to lead Company through next stage of development with focus on upcoming VIVIAD trial readout in 1Q24To-Date, varoglutamstat has demonstrated potential for meaningful safety and ease of use advantages over antibody-based therapies, continues to show encouraging...
Nasdaq GlobeNewswire
04/08/2023

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September…

PARIS and CAMBRIDGE, Mass., Aug.04, 2023(GLOBE NEWSWIRE) --NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer,today announced that the Company will host an Extraordinary General Meeting of Shareholders (“EGM”) on September 1 st, 2023 at 02:00 pm CEST at its headquarters.In order to implement the set of agreements disclosed in the...
Nasdaq GlobeNewswire
04/08/2023

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

The Notification Letter does not impact the Company's listing on the Nasdaq at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until January 29, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company's common shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by January 29, 2024…
PR Newswire
04/08/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 12convertible bonds in Oxurion resulting in a EUR 300 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US...
Nasdaq GlobeNewswire
04/08/2023
Altri  Comunicati